Mimedx (MDXG) Return on Capital Employed (2011 - 2026)
Mimedx (MDXG) posted Return on Capital Employed of 3.41% for Q2 2026, down 75.76% sequentially from 14.08% in Q1 2026, and down 1517.0% YoY from 0.24% in Q2 2025.
Mimedx (MDXG) Return on Capital Employed (2011 - 2026) Analysis & Trends
Mimedx has reported Return on Capital Employed for 15 years, with the latest figure at 3.41% in Q2 2026.
- Quarterly Return on Capital Employed fell 1517.0% year-over-year to 3.41% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 3.41% (down 1517.0% YoY) and the FY2025 annual result came in at 26.73%, down 186.0% from the prior year.
- Return on Capital Employed slipped to 3.41% in Q2 2026 per MDXG's latest filing, from 14.08% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 34.03% in Q2 2024 and troughed at 19.82% in Q3 2022.
- A 5-year average of 12.7% and a median of 20.18% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2025: Return on Capital Employed jumped 4350 bps in 2023, then plunged 1544 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 11.46% in 2022, then surged by 293 bps to 22.09% in 2023, then grew by 28 bps to 28.26% in 2024, then retreated by 15 bps to 23.97% in 2025, then sank by 86 bps to 3.41% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 3.41%, 14.08%, and 23.97% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Mimedx | 622.24 Mn | 486.40 Mn | 44.38 Mn | 3.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.41% |
| Mar 31, 2026 | 14.08% |
| Dec 31, 2025 | 23.97% |
| Sep 30, 2025 | 21.78% |
| Jun 30, 2025 | 18.59% |
| Mar 31, 2025 | 24.01% |
| Dec 31, 2024 | 28.26% |
| Sep 30, 2024 | 32.45% |
| Jun 30, 2024 | 34.03% |
| Mar 31, 2024 | 26.92% |
| Dec 31, 2023 | 22.09% |
| Sep 30, 2023 | 23.68% |
| Jun 30, 2023 | 11.51% |
| Mar 31, 2023 | -4.47% |
| Dec 31, 2022 | -11.46% |
| Sep 30, 2022 | -19.82% |
| Jun 30, 2022 | -13.93% |
| Mar 31, 2022 | -6.57% |
| Dec 31, 2021 | -4.97% |
| Sep 30, 2021 | -17.19% |